Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2-
advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment
for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.